Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

Prostate

Volumn 73, Issue 2, 2013, Pages 113-120

  Robert, Grégoire ^a,b   Jannink, Sander ^c   Smit, Frank ^c   Aalders, Tilly ^a   Hessels, Daphne ^c   Cremers, Ruben ^a   Mulders, Peter F ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL PELLEGRIN   (France)

^c NovioGendix   (Netherlands)

Author keywords

biomarker; diagnosis; gene fusion; PCA3; prostate cancer; TMPRSS2:ERG

Indexed keywords

COMPLEMENTARY DNA; HYBRID PROTEIN; MESSENGER RNA; ONCOPROTEIN; PROSTATE CANCER GENE 3; TMPRSS2 ERG FUSION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA ISOLATION; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84871613674     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22546     Document Type: Article

References (28)

1. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.
2. Salagierski M, Schalken JA,. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion. J Urol 2012; 187 (3): 795-801.
3. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54 (5): 1081-1088.
4. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun FK,. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010; 58 (5): 727-732.
5. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D,. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58 (4): 475-481.
6. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
7. Vanaja DK, Cheville JC, Iturria SJ, Young CY,. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63 (14): 3877-3882.
8. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA,. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56 (2): 275-286.
9. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA,. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13 (17): 5103-5108.
10. Levy DA, Jones JS,. Management of rising prostate-specific antigen after a negative biopsy. Curr Urol Rep 2011; 12 (3): 197-202.
11. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A,. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009; 55 (3): 600-606.
12. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN,. Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest 2005; 85 (1): 154-159.
13. Schalken JA,. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 2010; 58 (1): 19-20.
14. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y,. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93 (14): 1054-1061.
15. Ptolemy AS, Rifai N,. What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema. Scand J Clin Lab Invest Suppl 2010; 242: 6-14.
16. Floriano-Sanchez E, Cardenas-Rodriguez N, Castro-Marin M, Alvarez-Grave P, Lara-Padilla E,. DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Clin Invest Med 2009; 32 (6): E258.
17. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A,. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006; 66 (14): 1521-1534.
18. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, Schalken JA,. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70 (1): 10-16.
19. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J,. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184 (5): 1947-1952.
20. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG,. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15 (14): 4706-4711.
21. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE,. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23 (10): 1325-1333.
22. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA,. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31 (6): 882-888.
23. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA,. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21 (2): 67-75.
24. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS,. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007; 26 (18): 2667-2673.
25. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA,. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14 (11): 3380-3385.
26. van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA,. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007; 67 (8): 881-887.
27. Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schroder FH,. Predictors for biopsy outcome in the European randomized study of screening for prostate cancer (Rotterdam region). Prostate 1999; 39 (4): 316-322.
28. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG,. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011; May 19 [Epub ahead of print].